SCHEMBL963653

SCHEMBL963653

CC(C)(C)COC(=O)Nc1cccnc1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 3/20 0.55
NPC1 O15118 5/20 0.52
RAB9A P51151 5/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
AAK1 Q2M2I8 1/20 0.51
PKM P14618 2/20 0.50
CHRNA7 P36544 1/20 0.50
TSHR P16473 1/20 0.50
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
KDM4E B2RXH2 2/20 0.49
LMNA P02545 2/20 0.49
MAPT P10636 1/20 0.49
HTT P42858 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
HIF1A Q16665 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3269780 0.85 RAB9A (0.50) NAMPTNPC1RAB9APKMCHRNA7
SCHEMBL30058651 0.83 NPC1 (0.59) NAMPTNPC1RAB9APKMCHRNA7
SCHEMBL966665 0.83 NPC1 (0.59) NAMPTNPC1RAB9APKMCHRNA7
SCHEMBL22978789 0.81 RAB9A (0.56) NAMPTNPC1RAB9APKMCHRNA7
SCHEMBL14349237 0.81 RAB9A (0.54) NPC1RAB9ASMN1; SMN2TSHRLMNA
SCHEMBL965412 0.81 NPC1 (0.60) NPC1RAB9ASMN1; SMN2PKMCHRNA7
SCHEMBL27129536 0.80 RAB9A (0.54) NAMPTNPC1RAB9APKMCHRNA7
SCHEMBL349933 0.80 NAMPT (0.80) NAMPTNPC1RAB9ASMN1; SMN2PKM
SCHEMBL29457342 0.80 NAMPT (0.80) NAMPTNPC1RAB9ASMN1; SMN2PKM
SCHEMBL30352411 0.79 ALDH1A1 (0.53) NAMPTNPC1RAB9ASMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471775-A1 Manufacturing method for a piperidine-3-ylcarbamate compound and optical resolution method therefor SUMITOMO CHEMICAL CO., LTD. (JP) 2012-07-04 EP disclosed
US-20110021780-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-01-27 US disclosed
EP-2269986-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR Sumitomo Chemical Company, Limited (JP) 2011-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021780-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR PDCD2L, NOTUM, OXA1L NAMPT 877/4885NPC1 2998/4885RAB9A 2197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.